Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SHE:002932)
China · Delayed Price · Currency is CNY 15.18
-0.04 (-0.26%)
Aug 14, 2026, 3:04 PM CST
SHE:002932 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 265.79 | 265.08 | 350.06 | 749.54 | 10,530 | 2,830 |
Revenue Growth | -25.98% | -24.28% | -53.30% | -92.88% | 272.12% | 195.05% |
Gross Profit Gross Profit Growth | 110.25 | 86.16 | 132.31 | 439.82 | 6,538 | 2,122 |
Operating Income Operating Income Growth | -186.87 | -205.13 | -146.31 | -7.11 | 5,135 | 1,683 |
Net Income Net Income Growth | -13.18 | -16.46 | 74.52 | 74.93 | 4,208 | 1,413 |
Earnings Per Share EPS Growth | -0.06 | -0.07 | 0.33 | 0.33 | 18.31 | 6.68 |
EPS Growth | - | - | 0% | -98.20% | 174.19% | 197.11% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 |
In Vitro Diagnostic Products and Solutions In Vitro Diagnostic Products and Solutions Growth | 220.05 | 220.14 | 393.38 | 9,971 |
Business Operations and Others Business Operations and Others Growth | 45.02 | 129.92 | - | - |
Total Total Growth | 265.08 | 350.06 | 749.54 | 10,530 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 2,852 | 3,885 | 1,409 | 1,241 | 4,578 | 1,890 |
Total Debt Total Debt Growth | 24.26 | 7.72 | 13.11 | 49.16 | 203.59 | 44.36 |
Net Cash (Debt) Net Cash Growth | 2,827 | 3,877 | 1,396 | 1,192 | 4,375 | 1,846 |
Net Cash Growth | -11.96% | 177.78% | 17.14% | -72.76% | 137.02% | 153.67% |
Net Cash Per Share Net Cash Per Share Growth | 12.88 | 16.49 | 6.18 | 5.25 | 19.03 | 8.72 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -66.29 | -70.05 | -85.05 | 392.5 | 4,013 | 1,127 |
Capital Expenditures CapEx Growth | -62.61 | -90.89 | -184.77 | -109.97 | -313.38 | -103.57 |
Free Cash Flow Free Cash Flow Growth | -128.9 | -160.95 | -269.81 | 282.52 | 3,699 | 1,023 |
Free Cash Flow Growth | - | - | - | -92.36% | 261.47% | 208.82% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 41.48% | 32.50% | 37.80% | 58.68% | 62.09% | 75.00% |
Operating Margin | -70.31% | -77.38% | -41.80% | -0.95% | 48.77% | 59.47% |
Pretax Margin | -21.55% | -24.07% | 9.26% | 18.66% | 48.21% | 59.88% |
Profit Margin | -4.96% | -6.21% | 21.29% | 10.00% | 39.97% | 49.94% |
FCF Margin | -48.50% | -60.72% | -77.08% | 37.69% | 35.13% | 36.17% |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 1.230 | 0.120 | 3.490 | 2.027 |
Dividend Per Share Growth | 925.00% | -96.56% | 72.18% | 214.98% |
Dividend Yield | 7.09% | 0.56% | 10.50% | 7.41% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | 55.06 | 71.28 | 2.13 | 5.49 |
P/FCF Ratio | - | - | - | 18.91 | 2.42 | 7.58 |
PS Ratio | 12.53 | 15.88 | 11.72 | 7.13 | 0.85 | 2.74 |